Member Info for doze

There is some sort of deal going down between parties off the market and I don't think you can assume sale or buy. The reason I think this is because the MMs are not working the market to create liquidity.

http://www.lse.co.uk/share-regulatory-news.asp?shareprice=BSV&ArticleCode=ep80rgr0&ArticleHeadline=Interim_Results_and_Change_of_Company_Secretary notice it has been selected by BSV and has excellent growth record and sp shooting up, perhaps due to lack of stock. http://www.gamma.co.uk/media/1842/infographic_2014-v2.pdf http://www.gamma.co.uk/investors/company-reports/

Tissue Regenix is currently developing a process for decellularising donated human meniscus, based on the porcine dCELL® Meniscus, which is starting a regulatory human clinical trial in the EU to secure a CE mark. Like the animal tissue product this would be a piece of decellularised human meniscus for use in partial meniscal replacement (which accounts for 80% of procedures) rather than as a full transplant. http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12161535.html I did wonder why human tissue was not being used and nice that it is donated-a bit gruesome though.

Its a cart and horse situation. The drugs are the cart but the horse is the finance/nasdaq listing/liquidity.

Just one year's patience for me - see that dip from 3/10 when insiders must have started acquiring - do you think! If I had been persuaded to sell at 105 p on 14/10 I would be feeling murderous now.

made an emphatic statement recently that he did not want Russia to enter a new cold war and be isolated from the West but that does not mean he does not want to tow the line, he wants to win on the capital market arena and hopefully that is good for us. Pleased to hear about the MyeloXen progress therefore.

http://screencast.com/t/cdqqnc9Jlq9v

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12157404.html 41,000 ordinary shares of US$1.00 each in Chi-Med (the "Shares") at a price of GBP13.50 per share on 18 November 2014. = £553,500 Caused a nice s p rise.

44% invested by 5/11, judging by the sp they must be good investments. More of the same should see feet at £12 when fully invested.

You would have thought the SP would have responded to this a bit.

Will they be hamstrung because major shareholder will not agree to the issue of more equity? I would suggest Baxter attempt a buyout of obstructing interests.

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/12131946.html Received a preliminary positive decision from the Centers for Medicare & Medicaid Services (CMS) for the assignment of a permanent Healthcare Common Procedure Coding System (HCPCS) Q-code for DermaPure®, allowing for wound care centre reimbursement for the product, expected from January 2015 onwards http://patients.about.com/od/costsconsumerism/a/hcpcscodes.htm

Rusty is on the POG board. Will FGP win the UK East Coast Main Line next month? Would be a nice boost for those holding this.

http://www.lse.co.uk/ShareChart.asp?chart=intraday&sharechart=TRX&share=tissue_regenix

since rns

from rns-slow adoption as ever "Commercialisation of DermaPure™ continues to progress according to plan. We are working to gain further hospital product evaluation committee approvals as a trigger for future product adoption. We are also progressing in the enrolment of patients into human trials in the US. We look forward to discussions at SAWC as an opportunity to reach an even larger audience of US and global healthcare leaders." the acute wound market would be an easy one to tackle if kit is in place for the chronic market.

http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=12097599

http://www.proactiveinvestors.co.uk/companies/news/72691/tyratech-makes-significant-headway-72691.html

http://moneyweek.com/newsletters/#rhps

Interesting, I thought Asia would be largest portfolio % but it is EMEA 11.8% more http://www.londonstockexchange.com/exchange/news/market-news/market-news-detail.html?announcementId=12070196 Asia 34.3% EMEA 46.1% South America 19.6%